Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Rd therapy in elderly newly diagnosed multiple myeloma in western China
ChiCTR2000029925Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Mar 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lenalidomide, dexamethasone, bortezomib and ixazomib in multiple myeloma (MM), sponsored by West China Hospital of Sichuan University. Primary endpoints: overall survival and progression-free survival. Planned start Mar 2020; status: not yet recruiting.
02
Drugs
lenalidomidedexamethasonebortezomibixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2000029925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029925.